Keyphrases
Liver Transplantation
91%
Hepatocellular Carcinoma
74%
Nonalcoholic Steatohepatitis
63%
Non-alcoholic Fatty Liver Disease (NAFLD)
61%
Hepatitis C Virus
51%
Sorafenib
37%
Liver Transplant Recipients
36%
Cirrhosis
34%
Sofosbuvir
34%
Liver
31%
Ribavirin
30%
Fibrosis
30%
Serious Adverse Events
27%
Hepatic Decompensation
25%
Chronic Hepatitis C
25%
Advanced Hepatocellular Carcinoma
24%
Liver Disease
23%
Molecular Characterization
22%
Overall Survival
20%
Steatohepatitis
20%
Lipid Peroxidation
18%
Portal Hypertension
18%
Ascites
18%
Sustained Virological Response
17%
Chronic Liver Disease
17%
Liver Biopsy
17%
Refractory Ascites
17%
Transjugular Intrahepatic Portosystemic Shunt
17%
Hepatitis B
16%
Obesity
16%
Disease Progression
15%
Hazard Ratio
15%
Placebo
15%
Brivanib
14%
Treatment-related
14%
Pre-existing Liver Disease
14%
Acute Liver Failure
14%
Drug-induced Liver Injury
14%
Liver Decompensation
14%
Infected Patients
14%
Chronic Hepatitis B
14%
Post-liver Transplantation
13%
Modified Response Evaluation Criteria in Solid Tumors (mRECIST)
13%
Mount Sinai
13%
Metabolic Syndrome
13%
Molecular Classification
13%
Non-associated
12%
United States
12%
MELD Score
11%
Aminotransferase Activity
11%
Medicine and Dentistry
Nonalcoholic Fatty Liver
100%
Liver Transplantation
80%
Hepatocellular Carcinoma
65%
Hepatitis C Virus
43%
Fibrosis
43%
Liver Graft
40%
Infection
36%
Liver Disease
30%
Hepatitis B
29%
Adverse Event
28%
Decompensated Liver Cirrhosis
28%
Sofosbuvir
22%
Ascites
22%
Antioxidant
22%
Drug Dose Regimen
22%
Hepatitis B Virus
21%
Liver Cirrhosis
20%
Lipid Peroxidation
18%
Ribavirin
17%
Injury
17%
Bilirubin
16%
Neoplasm
15%
Transjugular Intrahepatic Portosystemic Shunt
15%
Liver Biopsy
14%
Antiviral Therapy
14%
Disease
14%
Liver Function
13%
Lamivudine
13%
Chronic Hepatitis B
13%
Disease Exacerbation
13%
Chronic Liver Disease
13%
Sorafenib
12%
Metabolic Syndrome
12%
Steatosis
12%
Steatohepatitis
12%
Virus Infection
11%
Cancer Mortality
11%
Skin Manifestation
11%
Mitochondrial DNA
11%
Politef
11%
Foreign Born
11%
Hepatitis B Core Antibody
11%
Liver Cancer
11%
Antiapoptotic
11%
Prospective Study
11%
Cytoprotective Agent
11%
Phosphotransferase Inhibitor
11%
Elafibranor
11%
Nitrofurantoin
11%
Colon Carcinoma
11%
Pharmacology, Toxicology and Pharmaceutical Science
Liver Cell Carcinoma
86%
Nonalcoholic Fatty Liver
82%
Hepatitis C Virus
55%
Decompensated Liver Cirrhosis
42%
Adverse Event
37%
Sorafenib
36%
Fibrosis
31%
Liver Disease
31%
Ribavirin
29%
Sofosbuvir
25%
Hepatotoxicity
25%
Infection
24%
Liver Cirrhosis
24%
Antioxidant
22%
Overall Survival
22%
Hepatitis B
19%
Neoplasm
18%
Hepatitis B Virus
17%
Injury
17%
Bilirubin
16%
Brivanib
15%
Disease Exacerbation
14%
Solid Malignant Neoplasm
13%
Placebo
13%
Chronic Hepatitis B
13%
Chronic Liver Disease
13%
Steatosis
12%
Acute Liver Failure
12%
Toxic Hepatitis
12%
Virus Infection
11%
Skin Manifestation
11%
Pyruvate Dehydrogenase Kinase
11%
Phosphotransferase Inhibitor
11%
Hepatitis B Core Antibody
11%
Lamivudine
11%
Cytoprotective Agent
11%
Regorafenib
11%
Sofosbuvir Plus Velpatasvir
11%
Paracetamol
11%
Aminotransferase
11%
Mitochondrial DNA
11%
Pathophysiology
11%
Prospective Study
11%
Nitrofurantoin
11%
Hemostatic Agent
11%
Antiapoptotic
11%
Peginterferon
11%
Azithromycin
11%
Amiodarone
11%
Blood Clotting Factor 7
11%